Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RBS-001 vs Eylea in Neovascular AMD
NCT06470373Phase 3Not yet recruiting
- Sponsor
- Rophibio
- Start
- Jul 2025
- Primary completion
- Sep 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RBS-001 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Rophibio. Primary endpoint: Change in Best-Corrected Visual Acuity (BCVA) measured by ETDRS letter score at 8 weeks. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
RBS-001
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06470373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06470373.